Matches in DBpedia 2016-04 for { <http://dbpedia.org/resource/ADSB-FUB-187> ?p ?o }
Showing triples 1 to 60 of
60
with 100 triples per page.
- ADSB-FUB-187 abstract "ADSB-FUB-187 is an indazole-based synthetic cannabinoid. It is a potent agonist of the CB1 receptor with a binding affinity of Ki = 0.09 nM and an EC50 of 1.09nM. It was originally developed by Pfizer in 2009, being example 187 from patent WO 2009/106982. While it is the most tightly binding compound from this patent in terms of Ki, it is not the most potent compound at producing a CB1 mediated pharmacological effect, with at least 17 other compounds from the patent having lower EC50 values.".
- ADSB-FUB-187 casNumber "1185283-97-9".
- ADSB-FUB-187 iupacName "7-chloro-N-[(2S)-1-[2-(cyclopropylsulfonylamino)ethylamino]-3,3-dimethyl-1-oxobutan-2-yl]-1-[(4-fluorophenyl)methyl]indazole-3-carboxamide".
- ADSB-FUB-187 pubchem "44186812".
- ADSB-FUB-187 thumbnail ADSB-FUB-187_structure.png?width=300.
- ADSB-FUB-187 wikiPageID "47188258".
- ADSB-FUB-187 wikiPageLength "2745".
- ADSB-FUB-187 wikiPageOutDegree "14".
- ADSB-FUB-187 wikiPageRevisionID "703380193".
- ADSB-FUB-187 wikiPageWikiLink AB-FUBINACA.
- ADSB-FUB-187 wikiPageWikiLink ADB-FUBINACA.
- ADSB-FUB-187 wikiPageWikiLink Agonist.
- ADSB-FUB-187 wikiPageWikiLink Cannabinoid_receptor_type_1.
- ADSB-FUB-187 wikiPageWikiLink Category:Cannabinoids.
- ADSB-FUB-187 wikiPageWikiLink Category:Designer_drugs.
- ADSB-FUB-187 wikiPageWikiLink Category:Indazolecarboxamides.
- ADSB-FUB-187 wikiPageWikiLink Category:Indazoles.
- ADSB-FUB-187 wikiPageWikiLink EC50.
- ADSB-FUB-187 wikiPageWikiLink Indazole.
- ADSB-FUB-187 wikiPageWikiLink Ligand_(biochemistry).
- ADSB-FUB-187 wikiPageWikiLink Pfizer.
- ADSB-FUB-187 wikiPageWikiLink Synthetic_cannabinoids.
- ADSB-FUB-187 wikiPageWikiLinkText "ADSB-FUB-187".
- ADSB-FUB-187 c "26".
- ADSB-FUB-187 casNumber "1185283".
- ADSB-FUB-187 cl "1".
- ADSB-FUB-187 f "1".
- ADSB-FUB-187 h "31".
- ADSB-FUB-187 iupacName "7".
- ADSB-FUB-187 legalCa "Schedule II".
- ADSB-FUB-187 molecularWeight "564.07".
- ADSB-FUB-187 n "5".
- ADSB-FUB-187 o "4".
- ADSB-FUB-187 pubchem "44186812".
- ADSB-FUB-187 s "1".
- ADSB-FUB-187 smiles "CC[C@@H]NCC2=NNCC4=CC=CF".
- ADSB-FUB-187 stdinchi "1".
- ADSB-FUB-187 stdinchikey "UANJTRHQSBHCID-HSZRJFAPSA-N".
- ADSB-FUB-187 wikiPageUsesTemplate Template:Cannabinoid-stub.
- ADSB-FUB-187 wikiPageUsesTemplate Template:Cannabinoidergics.
- ADSB-FUB-187 wikiPageUsesTemplate Template:Cannabinoids.
- ADSB-FUB-187 wikiPageUsesTemplate Template:Drugbox.
- ADSB-FUB-187 wikiPageUsesTemplate Template:Reflist.
- ADSB-FUB-187 subject Category:Cannabinoids.
- ADSB-FUB-187 subject Category:Designer_drugs.
- ADSB-FUB-187 subject Category:Indazolecarboxamides.
- ADSB-FUB-187 subject Category:Indazoles.
- ADSB-FUB-187 hypernym Cannabinoid.
- ADSB-FUB-187 type ChemicalSubstance.
- ADSB-FUB-187 type Drug.
- ADSB-FUB-187 type ChemicalObject.
- ADSB-FUB-187 type Thing.
- ADSB-FUB-187 type Q8386.
- ADSB-FUB-187 comment "ADSB-FUB-187 is an indazole-based synthetic cannabinoid. It is a potent agonist of the CB1 receptor with a binding affinity of Ki = 0.09 nM and an EC50 of 1.09nM. It was originally developed by Pfizer in 2009, being example 187 from patent WO 2009/106982. While it is the most tightly binding compound from this patent in terms of Ki, it is not the most potent compound at producing a CB1 mediated pharmacological effect, with at least 17 other compounds from the patent having lower EC50 values.".
- ADSB-FUB-187 label "ADSB-FUB-187".
- ADSB-FUB-187 sameAs Q20707333.
- ADSB-FUB-187 sameAs Q20707333.
- ADSB-FUB-187 wasDerivedFrom ADSB-FUB-187?oldid=703380193.
- ADSB-FUB-187 depiction ADSB-FUB-187_structure.png.
- ADSB-FUB-187 isPrimaryTopicOf ADSB-FUB-187.